Fraser and colleagues describe the whole-genome sequencing (WGS) profiles of over 200 localized intermediate-risk prostate cancers. WGS has been widely used in research but not, thus far, in clinical settings. Herein, we consider the possible use of WGS in the field of precision oncology.
Refers to Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature541,359-364 (2017)